Почетна › Difuzni veliki B-ćelijski limfom › Охајо
Kliničke studije za Difuzni veliki B-ćelijski limfom u državi Охајо
25 studija za Difuzni veliki B-ćelijski limfom traži učesnike na lokacijama u državi Охајо.
Gradovi u državi Охајо
Zvanični tekst studije (na engleskom)
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- University Hospitals of Cleveland ( Site 0113), Cleveland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07519772A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002), Cincinnati
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of Cincinnati Medical Center ( Site 0156), Cincinnati
- University Hospitals of Cleveland ( Site 0155), Cleveland
- Fairview Hospital-Moll Cancer Center ( Site 0198), Cleveland
- и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT06890884Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Aultman Health Foundation, Canton
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Case Western Reserve University, Cleveland
- и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06649812A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07101328A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07188558A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- The Ohio State University (OSU), Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07226843Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Hematology Care - Kenwood, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06500273Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
Тражи се учесникОпсервациона студија
Узраст од 0 до 38 · Оба пола · Ажурирано 29. 10. 2026. · NCT06131801Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Case Western Reserve University, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06015880Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Case Western Reserve University, Cleveland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT05633615Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07676877Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT07225439Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT06536049Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 25. 8. 2026. · NCT05826535DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 7. 2026. · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- The Ohio state University, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 7. 2026. · NCT05077527A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 7. 2026. · NCT05131022The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
Тражи се учесникФаза 1/2
Узраст од 12 до 95 · Оба пола · Ажурирано 15. 4. 2026. · NCT04329728Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT04775745A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 10. 2025. · NCT05780034DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Toledo Clinic Cancer Center, Toledo
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 7. 4. 2023. · NCT04920617Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- University of Cincinnati, Cincinnati
- The Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 8. 2022. · NCT04502394Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.